Anondita Medicare Ltd FY26: A 112% Profit Explosion Riding on the Cobra Wave

Section 1 — At a Glance

Anondita Medicare Limited has delivered an exceptionally strong financial performance for the year ended March 31, 2026, driven by an aggressive structural shift in its core operational strategy. Total revenue from operations reached ₹137.42 crore for FY26, representing a remarkable 78.5% growth compared to ₹76.99 crore in the preceding fiscal year. This topline momentum was accompanied by an even sharper expansion in bottom-line profitability. Net profit for the year surged by 111.8% to ₹33.45 crore, up from ₹15.79 crore in FY25, highlighting substantial operating leverage as the company scaled its proprietary brand ecosystem.

While headline growth metrics remain robust, investors are closely monitoring an escalating working capital cycle. Trade receivables expanded significantly to ₹51.86 crore in FY26 from ₹26.75 crore in FY25, indicating that a substantial portion of the company’s incremental growth is currently locked up in credit extended to institutional clients and government procurement agencies. Furthermore, the company continues to execute a high-stakes capital expenditure program, investing ₹75 crore to expand its production capacity by 1,360 million pieces per annum. Capital deployment efficiency remains a key variable, as any prolonged delay in the stabilization and utilization of these new manufacturing lines could generate structural pressures on overall asset turnover metrics.

When operating cash flows systematically diverge from accounting profits due to institutional credit extensions, corporate liquidity structures become entirely dependent on capital allocation discipline. Investors must look beyond superficial revenue growth to analyze the velocity of cash conversion cycles. The upcoming quarters will test whether international market entries can optimize this operational balance.

Section 2 — Introduction

Anondita Medicare Limited, established as a public corporate entity in March 2024, has rapidly altered its identity from a quiet, behind-the-scenes contract packager into an aggressive, brand-led manufacturer in the sexual wellness and personal care landscape. The business originally traces its roots back to 1999, operating as a proprietorship under the oversight of its founding promoter, Mr. Anupam Ghosh. Through a formal Business Transfer Agreement executed on April 1, 2024, the entire running infrastructure was consolidated into the current corporate corporate shell.

The company made its public market debut on September 1, 2025, raising ₹65.5 crore through an Initial Public Offering (IPO) on the NSE SME platform to fund its technical capacity scale-up and support escalating working capital requirements. Operating out of its primary manufacturing hub in Noida, Uttar Pradesh, the company has historically catered to institutional supply chains and major pharmaceutical organizations. However, its recent strategic focus centers heavily on building out its own proprietary product lines, creating a dual-engine operational model that balances steady, long-term government procurement contracts with high-margin retail expansion.

Section 3 — Business Model: WTF Do They Even Do?

At its core, Anondita Medicare is in the business of manufacturing protection, though its strategic positioning has more moving parts than a late-night infomercial. The company handles everything from raw material processing down to 100% electronic testing and in-house printing and packaging at its 9,290 square meter Noida facility. For years, the company was the ultimate corporate wingman, quietly contract-manufacturing for major national brands like Mankind Pharma’s “Manforce” and supplying global health players like Zydus.

Now, management has decided it wants the spotlight all to itself. They are aggressively pushing their own flagship brand, “COBRA”—a name that leaves absolutely nothing to the imagination. The revenue model is split between selling flavored male condoms to the retail trade and bidding for large-scale institutional tenders from the Government of India, including the Contraceptive Social Marketing Society (CMSS) and National AIDS Control Organisation (NACO).

To make things spicier, they have secured a manufacturing patent for female condoms. Management is betting big on this underserved global segment because female condoms command a staggering 30% to 40% premium in profit margins compared to traditional male variants. It is a classic volume-meets-value play, provided they can actually convince global healthcare agencies to hand over the procurement keys.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

The financial trajectory for the second half of FY26 reveals a business operating at full throttle. Revenue for H2 FY26 touched ₹83.32 crore, soundly beating the previous periods and proving that the “COBRA” brand is finding its bite in the domestic trade channels. Operating profit for the half-year doubled to ₹31.90 crore, driven by expanding operational scale and an improved product mix that favors their own high-margin branded products over low-yielding third-party manufacturing jobs.

Management said: “The additional capacity of 307 million pieces was added towards the end of Feb 2026, which means only an 8% to 10% utilization of that capacity could be captured in the FY26 numbers.”

This is classic corporate framing for “you haven’t even seen our final form yet.” While management swagger is highly visible in their forward projections, the numbers back them up for now, with EBITDA margins expanding by 327 basis points during the half-year.

Section 5 — Valuation Discussion: Fair Value Range Only

To evaluate where Anondita Medicare stands in the valuation spectrum, we look at its restated financial metrics for the full year of FY26. The company has 1.81 crore adjusted equity shares outstanding. With a reported full-year Net